RNS Number : 2555L
Genedrive PLC
29 December 2022

genedrive plc
("genedrive" or the "Company")

Result of AGM

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed.

For information, details of the proxy voting are shown below:

Resolutions	Votes For	Vote For (as % of votes cast)	Votes Against	Votes Against (as % of votes cast)	Vote Withheld
1	9,314,654	95.9%	396,009	4.1%	749,665
2	8,398,949	82.0%	1,847,623	18.0%	213,756
3	7,804,248	79.2%	2,045,968	20.8%	610,112
4	7,804,248	79.9%	1,958,332	20.1%	697,748
5	6,887,924	68.5%	3,165,195	31.5%	407,209
6	6,474,868	74.7%	2,193,549	25.3%	1,791,911
7	8,676,922	88.1%	1,173,294	11.9%	610,112
8	8,646,108	93.4%	608,071	6.6%	1,206,149
9	8,031,215	84.1%	1,515,314	15.9%	913,799
10	7,205,751	75.3%	2,357,879	24.7%	896,698

The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website (www.genedriveplc.com).

Although all the resolutions were passed, the Board of genedrive notes that more than 20% of votes were cast against the reappointment of certain directors and the resolution to generally disapply pre-emption rights (subject to certain limits). While the Board believes that all these directors bring considerable experience and expertise to the Board, it intends to engage with shareholders to better understand their concerns on the resolutions.

For further details please contact:

genedrive plc +44 (0)161 989 0245
David Budd: CEO / Russ Shaw: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker) +44 (0)20 7418 8900
James Steel / Oliver Duckworth

finnCap (Joint Broker) +44 (0)20 7220 500
Geoff Nash / George Dollemore / Nigel Birks / Alice Lane

Walbrook PR Ltd (Media Relations & IR) +44 (0)20 7933 8780
or genedrive@walbrookpr.com
Paul McManus / Anna Dunphy +44 (0)7980 541 893

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBIBDDLGDDGDC